Zoetis
ZTS
$71.55
+0.31%
Zoetis Inc. is the world's largest animal health company, discovering, developing, and manufacturing vaccines, anti-infectives, parasiticides, diagnostics, and other health products for companion animals (dogs, cats, horses) and production animals (cattle, swine, poultry, fish). Roughly 65% of revenue comes from companion animal products and 35% from production animals, with the U.S. business skewed even more heavily toward pets while international revenue leans toward livestock. The company was carved out of Pfizer's animal health unit and listed publicly in 2013, and it holds the largest market share in an industry characterized by high barriers to entry, long product cycles, and recurring demand tied to pet ownership and protein consumption. The current investor narrative has turned sharply negative: after a mixed Q4 2025 print that beat on EPS but showed declining growth in key segments, analysts have openly questioned Zoetis' pathway to growth, and the stock has suffered a violent re-rating as investors debate whether competitive pressure in parasiticides and companion animal therapeutics represents a cyclical air pocket or a structural loss of share.…
ZTS
Zoetis
$71.55
Related headlines
Investment Opinion: Should I buy ZTS Today?
The synthesized recommendation is Hold. The core thesis is that Zoetis is a high-quality franchise trading at a distressed valuation, but the lack of revenue growth and negative momentum warrant caution until there is evidence of a turnaround. The analyst consensus rating of 'buy' with an average target of $96.00 implies 37.8% upside, but the wide target range of $80 to $155 and the recent downgrade by William Blair suggest low conviction. The stock's forward PE of 10.66x is attractive, but it is contingent on earnings doubling to $9.06, which seems unlikely without a revenue inflection.
Supporting evidence for a Hold includes the company's strong gross margin of 72.73%, which remains above historical levels and indicates pricing power. Free cash flow of $2.366 billion provides a 4.2% FCF yield, and the dividend yield of 1.59% with a payout ratio of 33.3% is sustainable. However, revenue growth of 0.33% and operating margin compression to 37.97% are red flags. The stock trades at a PS ratio of 5.89x, which is moderate for a high-margin business, but the PB ratio of 16.75x is extreme due to leverage. The implied upside to the average analyst target is significant, but the market is pricing in outcomes below the most bearish analyst target, indicating skepticism.
The biggest risks that could invalidate the thesis include a continued decline in companion animal revenue, further margin erosion, and a breakdown below the 52-week low of $68.78. The rating would upgrade to Buy if revenue growth accelerates above 3% year-over-year and operating margins stabilize above 38%, or if the stock breaks above the $78 resistance level with strong volume. It would downgrade to Sell if revenue growth turns negative or if the stock decisively breaks below $68.78. Relative to its history, the stock is undervalued on PE and PS, but the low multiple may be a value trap until growth returns. The valuation verdict is that the stock is fairly valued to slightly undervalued, but with high uncertainty.
Sign up to view all
ZTS 12-Month Price Forecast
The forward-looking view is neutral with medium confidence. The company's revenue growth has stalled, and operating margins are compressing, which could continue to pressure the stock. However, the valuation is deeply discounted on a forward basis, and the analyst consensus remains bullish with a $96 target. The key tension is whether the companion animal slowdown is temporary or structural. I would upgrade to bullish if revenue growth accelerates above 3% and operating margins stabilize, or downgrade to bearish if revenue turns negative or the stock breaks below $68.78. The risk/reward is balanced, with significant upside if the turnaround materializes but substantial downside if the decline continues.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Zoetis's 12-month outlook, with a consensus price target around $96.00 and implied upside of +34.2% versus the current price.
Average Target
$96.00
0 analysts
Implied Upside
+34.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$80 - $155
Analyst target range
Fourteen analysts cover Zoetis with a consensus recommendation of "buy" (recommendation mean of 2.29 on a scale where lower is more bullish), and an average price target of $96.00 — implying +37.8% upside from the current $69.69. The consensus leans moderately bullish, but the distribution of recent institutional ratings reveals growing caution: of the ten most recent actions, TD Cowen (Buy), BNP Paribas (Outperform), Citigroup (Buy), and JP Morgan (Overweight) remain constructive, while Stifel (Hold), Piper Sandler (Neutral), UBS (Neutral), and Morgan Stanley (Overweight) sit on the sidelines. The most telling signal is William Blair's downgrade from Outperform to Market Perform on August 6, 2026 — the only rating change in the dataset — which suggests at least one house has thrown in the towel on near-term outperformance even as the consensus target remains far above the market price.
The target range of $80.00 to $155.00 is extraordinarily wide — a 94% spread between low and high — which signals deep disagreement about the company's fundamental trajectory and low conviction in any single outcome. The high target of $155.00 implies roughly 122% upside and would require a full multiple re-rating back toward historical levels plus a resumption of double-digit earnings growth, essentially assuming the current slowdown is a transient shock. The low target of $80.00 implies just 14.8% upside and prices in continued margin compression, competitive share loss in parasiticides and companion animal therapeutics, and a permanently lower growth algorithm. Notably, even the lowest analyst target sits 14.8% above the current price, meaning the sell-side collectively believes the stock is oversold — but the fact that the market trades 13% below the most bearish target suggests investors are pricing in outcomes the analyst community has not yet formally modeled, a classic setup for further estimate cuts. With consensus 2026 EPS of $9.06 and revenue of $10.85 billion, the credibility of the bullish case rests entirely on whether the Q2 2026 growth stall proves to be a trough.
Drowning in data?
Find the real signal!
Bulls vs Bears: ZTS Investment Factors
The bear case currently has stronger evidence, as the company's revenue growth has stalled to 0.33% year-over-year, operating margins are compressing, and the stock is in a severe technical downtrend with no clear support. However, the bull case rests on the stock's deeply discounted forward PE of 10.66x and the fact that even the lowest analyst target of $80 implies upside, suggesting the market may be pricing in an overly pessimistic scenario. The single most important tension is whether the companion animal slowdown is a cyclical air pocket or a structural loss of share; if it proves cyclical, the stock could re-rate sharply, but if structural, the low multiple is a value trap. The low beta of 0.729 and the company-specific nature of the selloff mean that any positive inflection in revenue growth could trigger a violent short-covering rally, but the burden of proof remains on the bulls to demonstrate a turnaround.
Bullish
- Deep value on forward earnings: The forward PE of 10.66x is less than half the trailing PE of 20.87x, implying the market expects earnings to roughly double to the consensus 2026 EPS of $9.06. If even a portion of that estimate is realized, the stock is priced for a severe recession that may not materialize.
- Analyst targets imply large upside: The average analyst target of $96.00 represents 37.8% upside from the current $69.69, and even the lowest target of $80.00 implies 14.8% upside. Fourteen analysts maintain a consensus 'buy' rating with a recommendation mean of 2.29, suggesting the sell-side sees the selloff as overdone.
- Gross margin remains resilient: Q2 2026 gross margin of 72.73% actually improved from 72.28% a year earlier and 71.66% in Q1 2026, indicating pricing power and product mix are intact. This supports the view that the revenue slowdown is demand-driven rather than a structural erosion of competitive positioning.
- Strong balance sheet and cash generation: The current ratio of 3.03 signals ample short-term liquidity, and trailing free cash flow of $2.366 billion provides a 4.2% FCF yield. This cash generation funds a 1.59% dividend yield and aggressive buybacks that reduce share count and support EPS even with flat revenue.
Bearish
- Revenue growth has stalled completely: Q2 2026 revenue of $2.468 billion grew just 0.33% year-over-year, a dramatic deceleration from historical mid-single-digit growth. The multi-quarter trend shows revenue essentially flat for six quarters, raising concerns that the companion animal slowdown is structural rather than cyclical.
- Operating margin compression accelerating: Operating margin fell to 37.97% in Q2 2026 from 40.20% a year earlier, and EBITDA declined 14.4% to $927 million from $1.083 billion. With operating expenses of $858 million and SG&A of $592 million consuming a larger share of flat revenue, the company is losing operating leverage.
- Technical breakdown with no support: The stock trades at $69.69, just 1.1% above its 52-week low of $68.78, after a 31% collapse in four sessions in May 2026. A decisive break below $68.78 would open the door to price discovery with no historical reference points, and the maximum drawdown of -55.82% confirms a deep bear market.
- Valuation still not cheap on growth: The PEG ratio of 2.04 indicates the stock is not inexpensive relative to its growth rate, even after the collapse. The PB ratio of 16.75x is extreme and reflects a levered, buyback-depleted equity base, while the EV/EBITDA of 15.48x is rich for a business with flat revenue.
ZTS Technical Analysis
Zoetis is in a severe, sustained downtrend, with the shares down 52.4% over the trailing year and 44.7% year-to-date, a decline that accelerated dramatically in early May 2026 when the stock gapped from $111.22 on May 6 to $87.31 on May 7 and then to $76.67 by May 11 — a roughly 31% collapse in four sessions that erased years of gains. At the current price of $69.69, the stock is trading at just 1.1% above its 52-week low of $68.78 and 53.2% below its 52-week high of $148.79, meaning it sits essentially at the bottom of its 52-week range (approximately 1% of range). This positioning is the hallmark of a broken chart: rather than a value opportunity, the persistent inability to hold any bounce suggests distribution and capitulation rather than accumulation, and the maximum drawdown of -55.82% confirms this is a deep bear market for the shares.
Short-term momentum remains negative but is decelerating in its rate of decline: the stock is down 8.51% over the past month and 6.83% over three months, versus a 40.91% decline over six months and 52.43% over a year. The critical divergence is against the market — SPY is up 15.01% over one year and 12.86% YTD, producing a staggering relative strength of -67.44% over one year and -57.52% YTD, one of the worst relative performances in large-cap healthcare. The one-month relative strength of -9.10% versus SPY's +0.59% shows the underperformance persists even as the absolute decline moderates, and with the stock closing at $69.69 on October 2 versus a previous close of $69.10, the modest +0.85% daily gain is noise within a downtrend, not a reversal signal. Volume of roughly 5.26 million shares and a short ratio of 3.76 days suggest short interest is meaningful but not extreme, leaving room for further downside if sentiment does not improve.
Key technical levels are starkly defined: support sits at the 52-week low of $68.78, just $0.91 below the current price, and a decisive breakdown below that level would open the door to price discovery to the downside with no historical reference points. Resistance is layered far above, beginning with the $76-$78 congestion zone where the stock repeatedly failed between May and September 2026, then the $87-$111 gap zone from the May collapse, and ultimately the $148.79 52-week high. The beta of 0.729 indicates the stock is roughly 27% less volatile than the market on a historical basis, which is unusual for a name in freefall and implies the selloff is driven by company-specific fundamental concerns rather than broad market beta — meaning position sizing based on beta alone would understate the idiosyncratic risk here. A breakout above $78 would be the first sign of stabilization, while a breakdown below $68.78 would confirm the bear trend remains fully intact.
Beta
0.74
0.74x market volatility
Max Drawdown
-54.9%
Largest decline past year
52-Week Range
$69-$148
Price range past year
Annual Return
-49.9%
Cumulative gain past year
| Period | ZTS Return | S&P 500 |
|---|---|---|
| 1m | -5.6% | +0.9% |
| 3m | -4.7% | +3.4% |
| 6m | -39.3% | +14.4% |
| 1y | -49.9% | +16.2% |
| ytd | -43.2% | +14.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ZTS Fundamental Analysis
Zoetis' revenue trajectory has stalled: Q2 2026 revenue of $2.468 billion grew just 0.33% year-over-year versus $2.460 billion in Q2 2025, a dramatic deceleration from the mid-single-digit growth the company historically delivered. The multi-quarter trend shows revenue of $2.220B (Q1 2025), $2.460B (Q2 2025), $2.400B (Q3 2025), $2.387B (Q4 2025), $2.262B (Q1 2026), and $2.468B (Q2 2026) — essentially flat for six quarters, with the year-over-year comparison in Q2 2026 barely positive. Segment data reveals the drag: Dogs and Cats, the largest segment at $1.634 billion, dwarfs Cattle ($390M), Swine ($117M), Poultry ($115M), Fish ($83M), and Horses ($74M), so any softness in companion animal — the segment analysts flagged as sliding — disproportionately impacts the consolidated growth rate. With consensus 2026 revenue estimates of $10.85 billion against a roughly $9.5 billion 2025 base, the market is pricing in a reacceleration that the most recent quarter does not yet corroborate.
Profitability remains robust in absolute terms but is compressing at the margin: Q2 2026 net income of $691 million on $2.468 billion revenue produced a 28.0% net margin, down from 29.2% in Q2 2025 ($718M) and 30.0% in Q3 2025 ($721M). Gross margin of 72.73% in Q2 2026 was actually up from 72.28% a year earlier and above the 71.66% in Q1 2026, indicating pricing power and product mix remain intact at the gross line. However, operating margin slipped to 37.97% in Q2 2026 from 40.20% in Q2 2025, and EBITDA fell to $927 million from $1.083 billion a year ago — a 14.4% decline — as operating expenses of $858 million and SG&A of $592 million consumed a larger share of a flat revenue base. The company remains highly profitable for a specialty pharmaceutical manufacturer, but the direction of travel on operating leverage is negative, and the gap between the 70.5% gross margin and the 38.0% operating margin highlights how much of the cost structure is fixed and vulnerable to revenue stagnation.
Balance sheet and cash flow metrics present a mixed picture: the current ratio of 3.03 signals strong short-term liquidity, and ROE of 80.2% is exceptional, though it is flattered by a debt-to-equity ratio of 2.85 and an equity multiplier of 4.79 that reflect heavy leverage and years of buybacks. Free cash flow TTM of $2.366 billion against a $55.8 billion market cap implies an FCF yield of roughly 4.2%, which is respectable but not compelling for a company with flat growth. Q2 2026 operating cash flow of $655 million funded $117 million of capex (FCF of $538 million), $223 million of dividends, and $584 million of stock repurchases — a shareholder return program that exceeds free cash flow generation and is being sustained partly by drawing down cash from $1.941 billion to $1.476 billion during the quarter. The debt-to-equity of 2.85 and total-debt-to-capitalization of 74.6% indicate the company has prioritized buybacks and dividends over deleveraging, which amplifies both returns and risk if earnings continue to stagnate.
Quarterly Revenue
$2.5B
2026-06
Revenue YoY Growth
+0.3%
YoY Comparison
Gross Margin
72.7%
Latest Quarter
Free Cash Flow
$2.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ZTS Overvalued?
Because Zoetis is solidly profitable — Q2 2026 net income of $691 million and trailing EPS of $1.65 — the PE ratio is the appropriate primary metric. The trailing PE of 20.87x compares to a forward PE of just 10.66x, an extraordinarily wide gap that implies the market expects earnings to roughly double, consistent with consensus 2026 EPS estimates of $9.06 versus the current quarterly run-rate. However, this gap is also a warning: the forward multiple is only credible if the company delivers the estimated $9.06 in EPS, and with revenue growth at 0.33% YoY, the burden falls almost entirely on margin recovery and buyback-driven share count reduction — a fragile bridge that explains why the stock trades at a distressed-looking forward multiple rather than a growth premium.
Relative to the specialty and generic drug manufacturing sector, Zoetis screens as a mixed bag: the PS ratio of 5.89x and EV/Sales of 3.79x are moderate for a high-gross-margin (70.5%) animal health leader, but the PB ratio of 16.75x is extreme and reflects the levered, buyback-depleted equity base rather than a genuine premium on assets. The PEG ratio of 2.04 suggests the stock is not cheap relative to its growth rate even after the collapse, and the EV/EBITDA of 15.48x is roughly in line with large-cap pharma but rich for a business with flat revenue. The dividend yield of 1.59% and payout ratio of 33.3% are sustainable but unremarkable, and the PCF ratio of 19.21x indicates cash generation is valued at a premium to earnings — a sign the market still ascribes quality to the franchise even as it punishes the growth trajectory.
Historical context is damning: Zoetis' PE ratio has compressed from 31.6x in Q4 2024 and 29.2x in Q1 2025 to 20.9x today, while the PS ratio has fallen from 31.7x and 33.2x in those same periods to 5.89x — a roughly 82% compression in the sales multiple in under two years. The stock is trading near the bottom of its own multi-year valuation band on both PE and PS, which historically would signal a value opportunity; but the simultaneous collapse in revenue growth to near zero means the market is repricing the company's terminal growth rate, not merely applying a cyclical discount. Until revenue growth inflects, the low multiple is more likely a value trap than a value opportunity, and the forward PE of 10.66x will only prove justified if the company can demonstrate that the companion animal slowdown is temporary.
PE
20.9x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 21x~43x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.5x
Enterprise Value Multiple
Investment Risk Disclosure
Zoetis faces significant financial and operational risks. The company's revenue growth has stalled at 0.33% year-over-year in Q2 2026, with six consecutive quarters of essentially flat revenue around $2.4 billion, indicating a potential structural slowdown in its core companion animal segment. Operating margin has compressed to 37.97% from 40.20% a year earlier, and EBITDA fell 14.4% to $927 million, highlighting negative operating leverage as fixed costs weigh on a stagnant revenue base. The debt-to-equity ratio of 2.85 and total-debt-to-capitalization of 74.6% indicate heavy leverage, and the company's shareholder return program—$223 million in dividends and $584 million in buybacks in Q2 2026—exceeds free cash flow generation, forcing a drawdown in cash from $1.941 billion to $1.476 billion. This financial engineering supports EPS but amplifies risk if earnings continue to stagnate.
Market and competitive risks are mounting. The stock trades at a forward PE of 10.66x, which is only justified if earnings double to the consensus $9.06 EPS, a fragile bridge given flat revenue. The PEG ratio of 2.04 suggests the stock is not cheap relative to growth, and the PB ratio of 16.75x is extreme, reflecting a levered equity base. Competitive pressure in parasiticides and companion animal therapeutics has been flagged by analysts as a key concern, and the recent downgrade by William Blair to Market Perform underscores growing skepticism. With a beta of 0.729, the stock is less volatile than the market, but its 52.4% one-year decline versus SPY's 15.01% gain shows severe idiosyncratic underperformance, meaning the selloff is driven by company-specific issues that could persist if competitive threats intensify.
The worst-case scenario involves a continued decline in companion animal revenue, further margin compression, and a breakdown below the 52-week low of $68.78. If the stock breaks that level, it could enter price discovery to the downside, with the next psychological support potentially around $60 or lower. The maximum drawdown of -55.82% from the 52-week high of $148.79 illustrates the severity of the bear market, and from the current price of $69.69, a drop to the 52-week low represents a 1.3% loss, but a more severe scenario could see a 20-30% decline to the $50-$55 range if revenue growth turns negative. The analyst low target of $80 is above the current price, but if estimates are cut, that target could be revised downward, leaving investors with substantial losses.
FAQ
The key risks include financial, competitive, macro, and company-specific factors. Financially, revenue growth has stalled at 0.33% year-over-year, and operating margins have compressed to 37.97% from 40.20%, with EBITDA down 14.4%. Competitively, the company faces pressure in parasiticides and companion animal therapeutics, and a major competitor could launch a superior product. Macroeconomic weakness could reduce pet spending, though the low beta of 0.729 suggests less market correlation. Company-specific risks include a breakdown below the 52-week low of $68.78, which could trigger further selling, and the heavy debt load with a debt-to-equity of 2.85. The most severe risk is a structural loss of market share leading to negative revenue growth.
The 12-month forecast has three scenarios: a bull case with 25% probability targeting $96-$155, a base case with 50% probability targeting $80-$96, and a bear case with 25% probability targeting $55-$68.78. The base case is most likely, assuming revenue growth remains sluggish at 1-2% and the company meets the consensus EPS of $9.06. The bull case requires a revenue reacceleration and margin recovery, while the bear case assumes a structural slowdown and a break below the 52-week low. The average analyst target of $96 implies 37.8% upside, but the wide range of $80 to $155 reflects low conviction. The key assumption for the base case is that the companion animal slowdown is cyclical, not structural.
ZTS appears undervalued on a forward basis, with a forward PE of 10.66x compared to a trailing PE of 20.87x, implying the market expects earnings to double. The PS ratio of 5.89x and EV/EBITDA of 15.48x are moderate for a high-margin business, but the PB ratio of 16.75x is extreme due to leverage. Relative to its own history, the PE has compressed from 31.6x in Q4 2024 to 20.9x today, and the PS ratio has fallen from 31.7x to 5.89x, an 82% compression. The market is pricing in a permanent slowdown, but if growth returns, the multiple could re-rate significantly higher. The PEG ratio of 2.04 suggests the stock is not cheap relative to its growth rate, so the valuation is fair to slightly undervalued, with high uncertainty.
From a risk/reward perspective, ZTS is a speculative buy for value investors with a high tolerance for uncertainty. The stock trades at $69.69, just 1.1% above its 52-week low, and offers 37.8% upside to the average analyst target of $96.00. However, the company's revenue growth has stalled at 0.33% year-over-year, and operating margins are compressing, which could lead to further downside if the trend continues. The forward PE of 10.66x is attractive but hinges on earnings doubling to $9.06, a high bar given flat revenue. For those who believe the companion animal slowdown is temporary, the risk/reward is favorable, but conservative investors should wait for evidence of a turnaround.
ZTS is more suitable for long-term investment than short-term trading. The stock is in a severe downtrend with negative momentum, and the low beta of 0.729 suggests it is not a high-volatility trading vehicle, though it has experienced sharp moves. The company pays a modest dividend with a 1.59% yield and a sustainable 33.3% payout ratio, which supports a buy-and-hold strategy. Earnings visibility is low due to the revenue slowdown, so short-term trading is risky. A suggested minimum holding period is 2-3 years to allow for a potential turnaround in revenue growth and margin recovery. Investors should monitor quarterly earnings for signs of inflection before committing capital.